Get all premium features to the best stock analysis tool

Nyxoah Reports First Quarter 2026 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports First Quarter 2026 Financial and Operating Results Strong Genio launch in the U.S. drove 25% sequential quarterly U.S. revenue growth Continued clarity around HGNS and Genio reimbursement in the U.S. Mont-Saint-Guibert, Belgium – May 12, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2026. Q1 2026 Financial and Operating Highlights Financials U.S. net revenue first quarter 2026 was €4.3 million (gross revenue was €4.5 million), 25% sequential growth over net revenue fourth quarter 2025 Global net revenue first quarter 2026 was €6.4 million (gross revenue was €6.7 million), 13% sequential growth over net revenue fourth quarter 2025 Leading U.S. commercial indicators 62 new surgeons trained in Q1, bringing the total to 207 surgeons trained 34 new accounts activated in Q1, bringing the total to 91 active high-volume accounts 241 patients submitted under prior authorization and still pending at the end of Q1 U.S. reimbursement landscape – further clarified Medicare issued new C-Codes covering Genio and clarified facility and physician payments Commercial payers continued reimbursement under existing CPT codes 100% prior-authorization approval obtained on reviewed submissions with commercial payers and WISeR program As of March 31, 2026, cash, cash equivalents and financial assets amounted to €25.9 million.

Publication relating to transparency notifications

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), March 20, 2026 , 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Robert Taub / Robelga SRL On March 19, 2026, Nyxoah received a transparency notification from Robert Taub and related person Robelga SRL, following the crossing above the 3% threshold by Robelga SRL on December 30, 2025 (while the overall “group” participation did not change).

Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of Sales Foundation Established to Drive Significant Growth in 2026 Mont-Saint-Guibert, Belgium – March 19, 2026, 9:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year of 2025. Recent Financial and Operating Highlights Fourth quarter gross revenue of €6.3 million, resulting in net revenue of €5.6 million, which represents 347% year-over-year growth, driven by the first full quarter of US commercialization Full year gross revenue of €11.0 million, resulting in net revenue of €10.0 million, which represents 122% year-over-year growth Fourth quarter gross margin of approximately 64% Cash, cash equivalents and financial assets of €48.0 million at December 31, 2025 145 surgeons trained and 57 accounts activated in the U.S. since commercial launch in August 2025 Genio system consistently reimbursed by both commercial payors and Medicare to date Expanding manufacturing footprint to support global growth “The fourth quarter marked our first full quarter of U.S. commercialization, and we are very pleased with the strong momentum we generated which led to us exceeding our revenue expectations for the quarter,” commented Olivier Taelman, Nyxoah's Chief Executive Officer.

Publication relating to transparency notification

REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), March 13, 2026 , 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BNP Paribas Asset Management On March 11, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management SA.